Recent updates on CAR T clinical trials for multiple myeloma

Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturati...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Quande, Zhao, Juanjuan, Song, Yongping, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829852/
https://www.ncbi.nlm.nih.gov/pubmed/31684964
http://dx.doi.org/10.1186/s12943-019-1092-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829852/
https://www.ncbi.nlm.nih.gov/pubmed/31684964
http://dx.doi.org/10.1186/s12943-019-1092-1

Ejemplares similares